Related to Strong Phase II NSCLC Trial Data Still Not Translating into Phase III Successes

• Pfizer Gains Patent from Cell Signaling Technology to Enhance Companion Diagnostic Efforts
  
• FDA Issues Adventrx with Complete Response Letter for NSCLC Drug Candidate
  
• Pfizer Allies with Qiagen to Develop Companion Diagnostic for NSCLC Drug Candidate
  
• EC Clears Roche’s Tarceva as Monotherapy Against Metastatic NSCLC with EGFR Mutations
  
• Life Technologies to Develop Companion Diagnostic for GSK’s Cancer Immunotherapy
  
• Roche’s Cobas EGFR Mutation Test Granted CE Mark
  
• Cerulean Raises $15M to Continue Phase II Trial with NSCLC Nanodrug
  
• Qiagen Signs Two Biomarker Deals and Confirms Japanese Okay for EGFR Companion Dx
  
• Agennix Stops Phase II/III Talactoferrin Study in Sepsis Due to Higher Death Rates
  
• Novartis Pays Enanta $34M Up Front for Worldwide Rights to HCV NS5A Inhibitors
  
• Agennix Contracts DSM for Commercial Supply of a Dendritic Cell Mediated Immunotherapy
  
• Agennix Contracts Lonza for Commercial Manufacturing of Its Oral NSCLC Immunotherapy
  
• Vectura, Novartis' COPD Therapy Succeeds in Fourth Phase III Study
  
• Novartis Pays Genmab $2M to Tap into Bispecific Antibody Technology
  
• Pivotal Trial Support Provided for Lung Cancer Drug
  
• Geron Halts One Imetelstat Trial; Another ‘Doubtful’ to Advance
  
• Lack of Efficacy Halts Pivotal Tivantinib Lung Cancer Trial
  
• Novel Treatment for Most Common Type of Lung Cancer
  
• STA Licenses Cancer Cachexia Drug
  
• Response Genetics Offers New Test for Lung Cancer Biomarker